Sanofi’s Zimulti Goes To Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic & Metabolic Drugs Advisory Committee will review the obesity agent, formerly known as Acomplia, June 13.
You may also be interested in...
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
Vernalis And Servier Join Forces To Develop Oncology Candidates
Servier was attracted to Vernalis based on the firm’s development work with Novartis on another oncology compound, Vernalis CEO tells “The Pink Sheet” DAILY.